---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005009"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:13:22.477861+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025

## Summary
- ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.
- ANX007 for GA: Phase 3 ARCHER II enrollment on track for completion in 2H 2025; data expected 2H 2026.
- ANX1502 oral C1s inhibitor: clinical proof-of-concept data in CAD expected in 1Q 2025.
- Cash runway sufficient into 2H 2026 to achieve key milestones.
- Positive Phase 2 ARCHER data for ANX007 showed significant vision preservation on BCVA and LLVA endpoints.

## SEC filing metadata
- accession: 0001193125-25-005009
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/0001193125-25-005009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312525005009/d38866d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005009
- JSON: https://secwatch.observer/filing/0001193125-25-005009.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.